Nitrostat (nitroglycerin) — PFIZER

Acute episode of anginal pain
Pre-exertional prophylaxis of anginal pain
0.3 mg sublingual tablet
Place 1 tablet (0.3 mg) by sublingual route at the first sign of an attack; no more than 3 tabs are recommended within a 15 minute period.

0.4 mg sublingual tablet
Place 1 tablet (0.4 mg) by sublingual route every 5 minutes as neededfor chest pain. Do not exceed 3 doses in 15 minutes.

0.6 mg sublingual tablet
Place 1 tablet (0.6 mg) by sublingual route at 1St sign of attack; may repeat every 5 minutes up to 3 tabs; if no relief seek medical help

0.3 mg sublingual tablet
Place 1 tablet (0.3 mg) by sublingual route at the first sign of an attack; no more than 3 tabs are recommended within a 15 minute period.

0.4 mg sublingual tablet
Place 1 tablet (0.4 mg) by sublingual route every 5 minutes as neededfor chest pain. Do not exceed 3 doses in 15 minutes.

0.6 mg sublingual tablet
Place 1 tablet (0.6 mg) by sublingual route at 1St sign of attack; may repeat every 5 minutes up to 3 tabs; if no relief seek medical help

Acute episode of anginal pain
Dosage Type: Tablet, sublingual
Place 1 tablet (0.3 mg) by buccal route at the first sign of an attack; no more than 3 tabs are recommended within a 15 minute period.
Place 1 tablet (0.3 mg) by buccal route every 5 minutes until relief is obtained not to exceed 3 tablets in a 15-minute period
Place 1 tablet (0.3 mg) by sublingual route at the first sign of an attack; no more than 3 tabs are recommended within a 15 minute period.
Place 1 tablet (0.3 mg) by sublingual route every 5 minutes until relief is obtained not to exceed 3 tablets in a 15-minute period
Place 1 tablet (0.4 mg) by buccal route at 1St sign of attack; may repeat every 5 minutes up to 3 tabs; if no relief seek medical help
Place 1 tablet (0.4 mg) by buccal route at the first sign of an attack; no more than 3 tabs are recommended within a 15 minute period.
Place 1 tablet (0.4 mg) by buccal route every 5 minutes until relief is obtained not to exceed 3 tablets in a 15-minute period
Place 1 tablet (0.4 mg) by sublingual route at 1St sign of attack; may repeat every 5 minutes up to 3 tabs; if no relief seek medical help
Place 1 tablet (0.4 mg) by sublingual route at the 1St sign of attack; may repeat every 5 min until relief; if pain persists after 3 tablets in 15 min, prompt medical attention is recommended
Place 1 tablet (0.4 mg) by sublingual route every 5 minutes as neededfor chest pain. Do not exceed 3 doses in 15 minutes.
Place 1 tablet (0.4 mg) by sublingual route every 5 minutes until relief is obtained not to exceed 3 tablets in a 15-minute period
Place 1 tablet (0.6 mg) by buccal route at 1St sign of attack; may repeat every 5 minutes up to 3 tabs; if no relief seek medical help
Place 1 tablet (0.6 mg) by buccal route at the first sign of an attack; no more than 3 tabs are recommended within a 15 minute period.
Place 1 tablet (0.6 mg) by buccal route every 5 minutes until relief is obtained not to exceed 3 tablets in a 15-minute period
Place 1 tablet (0.6 mg) by sublingual route at 1St sign of attack; may repeat every 5 minutes up to 3 tabs; if no relief seek medical help
Place 1 tablet (0.6 mg) by sublingual route at the 1St sign of attack; may repeat every 5 min until relief; if pain persists after 3 tablets in 15 min, prompt medical attention is recommended
Place 1 tablet (0.6 mg) by sublingual route every 5 minutes until relief is obtained not to exceed 3 tablets in a 15-minute period

Pre-exertional prophylaxis of anginal pain
Place 1 tablet (0.3 mg) by buccal route 5-10 minutes prior to activities which might precipitate an attack
Place 1 tablet (0.3 mg) by sublingual route 5-10 minutes prior to activities which might precipitate an attack
Place 1 tablet (0.4 mg) by buccal route 5-10 minutes prior to activities which might precipitate an attack
Place 1 tablet (0.4 mg) by sublingual route 5-10 minutes prior to activities which might precipitate an attack
Place 1 tablet (0.6 mg) by buccal route 5-10 minutes prior to activities which might precipitate an attack
Place 1 tablet (0.6 mg) by sublingual route 5-10 minutes prior to activities which might precipitate an attack
Severe Warnings
Intracerebral hemorrhage
Intracranial hypertension
Methemoglobinemia
Severe anemia
Contraindicated
None
Moderate Warnings
Hypotension
Severe chronic heart failure
Less Frequent
Severe
None

Less Severe
Nausea
Palpitations
Tachycardia
Vomiting
More Frequent
Severe
Syncope

Less Severe
Dizziness
Flushing
Headache disorder
Hypotension
Nervousness
Orthostatic hypotension
Paresthesia
Rare / Very Rare
Severe
Allergic dermatitis
Anaphylaxis
Blurred vision
Exfoliative dermatitis
Methemoglobinemia
Severe headache disorder
Xerostomia

Less Severe
Drowsy
Dyspnea
General weakness
Skin rash
Vertigo
More information
No precaution information has been provided for this patient type.
Nitroglycerin
Severity Level: 2
Additional Notes: Insuff human data; animal data do not suggest developmental toxicity

More information
Contraindicated
None

Precaution Exists
Nitroglycerin
GeneralExcretion PotentialEffect on InfantNotes
Evaluate use carefullyUnknownNot known; no or inclusive dataInsufficient data available

No Known Risk
None
More information
Contraindicated
None

Precaution Exists
Nitroglycerin
Cardiovascular-Start at low end of dosing range. May be more sensitive to the hypotensive effects of vasodilation.
Organ / SystemHEPRENCARDENDONEURO / PSYCHPULM
Increased Risk / Adverse EffectsNNYNNN
BEERS: N   HEDIS: N   STOPP: Y

No Known Risk
None
Acute episode of anginal pain
I20Angina pectoris
I20.0Unstable angina
I20.1Angina pectoris with documented spasm
I20.8Other forms of angina pectoris
I20.9Angina pectoris, unspecified
I23.7Postinfarction angina
Pre-exertional prophylaxis of anginal pain
I20Angina pectoris
I20.9Angina pectoris, unspecified
I25.11Atherosclerotic heart disease of native coronary artery with angina pectoris
I25.119Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris
I25.7Atherosclerosis of coronary artery bypass graft(s) and coronary artery of transplanted heart with angina pectoris
I25.70Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris
I25.709Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris
I25.71Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris
I25.719Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris
I25.72Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris
I25.729Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris
I25.73Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris
I25.739Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris
I25.75Atherosclerosis of native coronary artery of transplanted heart with angina pectoris
I25.759Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris
I25.76Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris
I25.769Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris
I25.79Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris
I25.799Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris
0-9 A-Z
I20 Angina pectoris
I20 Angina pectoris
I20.0 Unstable angina
I20.1 Angina pectoris with documented spasm
I20.8 Other forms of angina pectoris
I20.9 Angina pectoris, unspecified
I20.9 Angina pectoris, unspecified
I23.7 Postinfarction angina
I25.11 Atherosclerotic heart disease of native coronary artery with angina pectoris
I25.119 Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris
I25.7 Atherosclerosis of coronary artery bypass graft(s) and coronary artery of transplanted heart with angina pectoris
I25.70 Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris
I25.709 Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris
I25.71 Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris
I25.719 Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris
I25.72 Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris
I25.729 Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris
I25.73 Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris
I25.739 Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris
I25.75 Atherosclerosis of native coronary artery of transplanted heart with angina pectoris
I25.759 Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris
I25.76 Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris
I25.769 Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris
I25.79 Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris
I25.799 Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris

Data included with permission and copyrighted by First DataBank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgement of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. Diagnosis codes are provided for reference only. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatement.